OMNIlife science Marks Nearly 4,000 U.S. OMNIPlasty™ Procedures

EAST TAUNTON, Mass., Sept. 15, 2014 /PRNewswire/ -- OMNIlife science, Inc. ("OMNI™"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announces surgeons have completed over 4,000 total knee replacements in the U.S. using the OMNIPlasty™ technique.  OMNIPlasty is a total knee replacement procedure that uses robotics, driven by the OMNI ART™ software platform, to optimize implant placement. Surgeons can meticulously plan and execute a procedure that is specific to each patient using a patented intra-operative 3-D modeling technique that is not dependent on pre-operative CT scans or x-rays.

In 2012, OMNI upgraded its orthopaedic navigation platform in anticipation of expansion into the U.S. markets.  The sleek, modular hardware design of the OMNINAV™ station and the OMNI ART software application that drives the robotics, uniquely qualifies OMNI to offer robotically optimized implant positioning in total knee replacement procedures.

The OMNI ART software is designed for flexibility and customization to any surgeon's particular philosophy, which may result in increased efficiency. Dr. Corey Ponder from Oklahoma Sports & Orthopedics Institute in Oklahoma City states, "The flexibility we have achieved using OMNI ART software is significant. When changes need to be made during surgery because of unforeseen circumstances, we are able to handle them easily and efficiently. When you combine that time savings with the robotic precision of OMNIPlasty, you have then taken total knee replacement to another level."

OMNI expects the demand for robotic precision in the total knee replacement market to increase dramatically.  Currently, OMNIPlasty surgeons are anxious to further their successes with the new platform. OMNI is dedicated to adopting novel technologies and designing high-performance implants. It is innovation from OMNI and partnership with surgeons that make OMNIPlasty possible.

"The new OMNINAV station has the look and feel of the future in orthopaedic navigation, which is validated by its extreme level of performance and accuracy.   OMNIPlasty offers the only robotically assisted total knee replacement technology on the market, which provides my patients with a custom-tailored solution for their knee arthritis problems," states Dr. Jan Koenig of Winthrop University Hospital in Long Island.

 "OMNI has always been on the cutting edge with its knee and hip replacement products.  I am pleased to see they have upped their game by providing surgeons with a sophisticated tool to optimize implant placement. The results achieved with OMNIPlasty in my practice are outstanding, and appear more so than other methods, including methods where computer navigation was used," states Dr. Leonid Dabuzhsky of Quincy Medical Center in Quincy, MA.

About OMNIlife science, Inc. (OMNI)

OMNI is a privately held company with a proprietary robotic navigation platform, OMNINAV™, which allows surgeons to conduct patient specific total knee surgery designed to enhance patient satisfaction, reduce hospital costs, and remove need for MRI and x-rays.  This technology provides surgeons the much needed option to adjust during the procedure and is designed to provide an accurate customized fit.  OMNI is an innovative and well-established hip and knee implant replacements engineering, manufacturing and distribution support company and is focused on providing cutting edge technologies to improve patient care.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., (OMNI) including its advance robotic plans and statements using the terms "plans," "confident" or similar expressions are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward looking statements after the date of this press release.

Contact:
OMNIlife science, Inc. (OMNI)
Robert Phelps
Senior Vice President, Sales & Marketing
Phone: (508) 824-2444

SOURCE OMNIlife science, Inc.